The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase epsilon

The recent discovery of mutations in the gene encoding diacylglycerol kinase epsilon (DGKE) identified a novel pathophysiologic mechanism leading to HUS and/or MPGN. We report ten new patients from eight unrelated kindreds with DGKE nephropathy. We combined these cases with all previously published...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Azukaitis K Karolis
Simkova E Eva
Majid MA Mohammad Abdul
Galiano Matthias
Benz Kerstin
Amann Kerstin
Bockmeyer Clemens
Gajjar Radha
Meyers Kevin E.
Cheong Hae II
Lange-Sperandio Bärbel
Jungraithmayr Therese
Bereczki Csaba
Csuka Dorottya
Prohászka Zoltán
Dokumentumtípus: Cikk
Megjelent: 2017
Sorozat:JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 28 No. 10
doi:10.1681/ASN.2017010031

mtmt:3269673
Online Access:http://publicatio.bibl.u-szeged.hu/17677
Leíró adatok
Tartalmi kivonat:The recent discovery of mutations in the gene encoding diacylglycerol kinase epsilon (DGKE) identified a novel pathophysiologic mechanism leading to HUS and/or MPGN. We report ten new patients from eight unrelated kindreds with DGKE nephropathy. We combined these cases with all previously published cases to characterize the phenotypic spectrum and outcomes of this new disease entity. Most patients presented with HUS accompanied by proteinuria, whereas a subset of patients exhibited clinical and histologic patterns of MPGN without TMA. We also report the first two patients with clinical and histologic HUS/MPGN overlap. DGKE-HUS typically manifested in the first year of life but was not exclusively limited to infancy, and viral triggers frequently preceded HUS episodes. We observed signs of complement activation in some patients with DGKE-HUS, but the role of complement activation remains unclear. Most patients developed a slowly progressive proteinuric nephropathy: 80% of patients did not have ESRD within 10 years of diagnosis. Many patients experienced HUS remission without specific treatment, and a few patients experienced HUS recurrence despite complete suppression of the complement pathway. Five patients received renal allografts, with no post-transplant recurrence reported. In conclusion, we did not observe a clear genotype-phenotype correlation in patients with DGKE nephropathy, suggesting additional factors mediating phenotypic heterogeneity. Furthermore, the benefits of anti-complement therapy are questionable but renal transplant may be a feasible option in the treatment of patients with this condition.
Terjedelem/Fizikai jellemzők:3066-3075
ISSN:1046-6673